rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GTCB 2007 ******

2.783 Posts
Pagina: «« 1 ... 33 34 35 36 37 ... 140 »» | Laatste | Omlaag ↓
  2. [verwijderd] 2 maart 2007 16:49

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Prett ik lees ook dat mensen van Insm naar Gtcb refereren. Ze zeggen dat zodra Insm goed nieuws krijgt dat ie dan instort net als gtcb. Sell on the news.
  5. [verwijderd] 2 maart 2007 18:47

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    waarom lees je 100x dezelfde vragen en opmerkingen

    GTC staat zo laag omdat er veel meer biotech bedrijven zijn in USA dan in Nederland
    zeg effe tig tigvoudige.

    verder heeft GTC er een zooitje van gemaakt afgelopen jaren, en daardoor ziet niemand veel heil in dit aandeel.
    beste gok is hopen op overname..maar wie wil het??
    dat het erg LAAG gewaardeerd is ben ik met iedereen eens, maar dat zie je daar wel vaker in USA.
    staan zat kleine biotech met veel minder aandelen uit ook tussen 1 en 1,50 dollar en zijn minstens zo interessant.

    Ik had ook meer gehoopt en ook wel wat meer verwacht van GTC. nooit een vetpot, maar wel meer
    Management laat dit bedrijf gewoon prive gaan desnoods (pink of zo) het interesseert ze niet.
    ze zien hun notering louter als geldbron imo en niet als verplichting om aandeelhouderswaarde te creeeren

    je mag 100x vergelijken met Pharming, maar dat is KUL.
    Pharming zal wel flink stijgen bij goedkeuringen..om de doodeenvoudige reden dat het hun zaakjes beter voor elkaar heeft..en hier veel minder biotech (succesvol met produkt dan op de markt) te vinden is.

    vergelijking INSM ook mank
    als INSM approval EU krijgt en geen last meer heeft van TRCA gaat dat echt wel omhoog
    Homosidesneh
  7. [verwijderd] 2 maart 2007 21:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GTC staat zo laag omdat er veel meer biotech bedrijven zijn in USA dan in Nederland
    zeg effe tig tigvoudige.

    Lijkt me onjuist. Als ze in de USA ergens kwaliteit in zien, dan stijgt de koers. Of er nu 10 of 100 bedrijven van zijn.

    Maar draai het eens om:
    Pharming staat zo hoog omdat er veel minder biotech bedrijven zijn in Nederland dan in USA zeg effe tigste deel.
    Als je in Biotech wil beleggen is er maar weinig keus dus koop je van ellende maar Pharming? Of is dit geen leuke gedachte?
  9. [verwijderd] 3 maart 2007 08:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Nostra,

    ik begin het nut van sommige reacties te verliezen.
    IHet begint te lijken dat sommigen bij voorbaat een beeld hebben als iemand post en dan maar beginnen om te proberen de zaak om te gaan draaien om zo wat discussie te forceren.

    In wezen zeg jij niets anders dan ik schrijf. Ik kan zelfs mee met je interpretatie zoals je hem schrijft mbt Pharming en Nederland.

    In wezen geef ik je dat ook aan in mijn stuk, maar ik geloof echt dat er hier meer gehakt wordt dan iets gelezen en begrepen.

    Juist omdat in Nederland er nauwelijks fatsoenlijke biotech is staat Pharming , Crucell vrij hoog. In USA is de keuze nogmaals vele malen groter, zodat het daar gewoon veel langer kan duren voordat eenbiotech bedrijf enige marktwaardering krijgt.
    Zeker wanneer DAAR een keer iets misgegaan is.

    Pharming zou in USA idd geen grof omgerekende 4,50 dollar staan hoe zij nu bezig zijn.
    Ben ik met je eens.

    GTC zou hier stuk hoger staan.

    Ik vind het jammer dat je in je postings steeds de confrontatie zoekt ipv eens inziet dat zeker ik gewoon weet waar ik over spreek mbt Pharming en materie, EMEA en FDA en hooguit positiever ben in zijn algemeenheid dan bijv jij , maar dat echt ZONDEr roze bril gaat

    die had ik ooit jaren terug..die is allang af
    Homosidesneh
  10. [verwijderd] 3 maart 2007 08:18

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GTC overigens deal met Pharmaathene gisteren nabeurs

    hetzelfde Pharmaathene wat onlangs nog 230 miljoen subsidie kreeg

    Eindelijk dus een deal die idd neigt naar voordelen van schaalgrootte

    Ben blij dat de technologie heel langzaam ook voor andere bedrijven interessant is .

    GTC Biotherapeutics Enters into Process Development and Clinical Supply Manufacturing Services Agreement with PharmAthene for Protexia®

    [GTC also stands to earn a royalty on Protexia sales for its IP license should there ever be any sales (#msg-4107224). Although PharmAthene has its own small goat herd that was inherited from Nexia (#msg-4831852), they presumably decided to do things the right way and go to the pros (GTC). PharmAthene has grants to develop Protexia from both the DoD and the NIH (see hyperlinks below). Those who voted “yes” on the latest survey win, although this may not have been the news they were expecting.]

    http://biz.yahoo.com/bw/070302/20070302005629.html?.v=1

    >>
    Friday March 2, 4:33 pm ET

    FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB ) and PharmAthene, Inc. have entered into an agreement under which GTC will provide process development and clinical supply manufacturing services for PharmAthene's Protexia® program. Protexia® is a recombinant form of human butyrylcholinesterase (rBChE) produced in the milk of transgenic goats, which is being developed by PharmAthene as a pre- and post-exposure therapy for military or civilian victims of a chemical nerve agent attack.

    "We are pleased to expand our relationship with PharmAthene to provide the processing and analytical expertise for the development of Protexia®," stated Geoffrey F. Cox, Ph.D., GTC's Chairman and Chief Executive Officer. "rBChE is a prime example of a protein that is difficult to express in other production systems and is well suited to the transgenic technology platform."

    "GTC is an industry leader in transgenic protein technology and we look forward to working with them to ensure that the manufacturing of Protexia® is developed in accordance with all the appropriate regulatory requirements," stated David P. Wright, President and Chief Executive Officer of PharmAthene.

    While the utility of human plasma derived butyrylcholinesterase (hBChE) to protect against nerve agent toxicity is well documented, a major limitation hindering its commercial development has been the inability to produce commercial quantities of hBChE due to a limited availability of appropriate blood supplies, low levels of the protein in plasma, and low production yields using traditional biotechnology methods. PharmAthene's recombinant hBChE overcomes these limitations by enabling substantially larger production yields than are possible using other expression systems or through purification of the native protein from human plasma. Transgenic production and manufacturing is estimated to be capable of supplying sufficient rBChE to make Protexia® available for use by the military and civilian populations.

    About Nerve Agents

    Organophosphate nerve agents, or anti-cholinesterase agents, cause toxicity by binding to and inhibiting acetylcholinesterase, an enzyme in the body that is essential for nervous system function. This leads to increases in acetylcholine and "cholinergic crisis" that can cause loss of muscle control, respiratory failure, paralysis, convulsions, permanent brain damage and eventually death.

    These so-called nerve gases, which are actually all liquids at room temperature, are lethal in low quantities when inhaled or absorbed through the skin. Nerve agents can be classified as either G-agents (sarin, soman, tabun) or V agents (VX), both of which are exceedingly volatile and toxic.

    About Protexia: Recombinant Human Butyrylcholinesterase

    Protexia® is a form of recombinant human butyrylcholinesterase (rBChE), a potent organophosphate (OP) scavenger protein produced in the milk of transgenic goats, which is being developed for use as a prophylactic and therapeutic against acute organophosphate (OP) nerve agent toxicity. In September 2006 PharmAthene was awarded a multi-year contract valued at up to $213 million from the Department of Defense (DoD) U.S. Army Space and Missile Command, for advanced development of Protexia® [see #msg-13565694. PharmAthene also has a larger Protexia grant from the NIH (#msg-14110344).]

    About PharmAthene, Inc.

    PharmAthene, a privately-held biotechnology company, was formed to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. PharmAthene's lead programs include Valortim(TM), a treatment for anthrax, and Protexia®, a treatment for nerve agent exposure. For more information on PharmAthene, please visit www.PharmAthene.com.

    About GTC Biotherapeutics, Inc.

    GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. In August 2006, ATryn®, GTC's recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. This was the first approval anywhere in the world of a therapeutic protein produced from a transgenic animal.

    GTC has also recently been granted a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is av
  12. [verwijderd] 3 maart 2007 08:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    1 A dus:)

    Het voordeel van het kunnen opvullen van het grote gebrek aan hoeveelheden (zelfde geldt voor Pharming)..wordt zo duidelijker ...
    While the utility of human plasma derived butyrylcholinesterase (hBChE) to protect against nerve agent toxicity is well documented, a major limitation hindering its commercial development has been the inability to produce commercial quantities of hBChE due to a limited availability of appropriate blood supplies, low levels of the protein in plasma, and low production yields using traditional biotechnology methods
    Homosidesneh
  13. [verwijderd] 3 maart 2007 09:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    daarom zie ik dus Pharming niet GTC achterna gaan na goedkeuring zoals anderen je nu doen geloven.

    doodeenvoudige reden dat er in Nederland nauwelijks succesvolle biotech te vinden is dan buiten Pharming, Crucell en beetje Fornix.

    In USA vind je er legio
    Homosidesneh
  14. $rob$ 3 maart 2007 09:07

    • $rob$

      Lid sinds: 01 jan 2000

      Laatste bezoek: 25 feb 2025

    • Aanbevelingen

      Ontvangen: 258

      Gegeven: 65

    •    Aantal posts: 1.967

    Overigens komt het PB van GTCB net op tijd. Hopelijk tilt dit bericht de koers in ieder geval weer boven de dollar. Van de jaarcijfers a.s. moeten we het niet hebben lijkt me.
    rob
  15. [verwijderd] 3 maart 2007 14:35

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Yahoo!My Yahoo!Mail Make Y! your home pageYahoo! SearchSearch:Sign In
    New User? Sign UpFinance Home -Help


    Home InvestingMarket OverviewMarket StatsStocksMutual FundsETFsBondsOptionsIndustriesCurrencyEducationNews & OpinionMarketsInvesting IdeasSmall BizExpert AdviceSpecial EditionsCompany FinancesProvidersPersonal FinanceBanking & BudgetingCareer & WorkCollege & EducationFamily & HomeInsuranceLoansReal EstateRetirementTaxesHow-to GuidesGet QuotesSymbol LookupFinance Search



    AP
    GTC Biotherapeutics in Development Deal
    Friday March 2, 5:39 pm ET
    GTC Biotherapeutics Inks Manufacturing Contract for PharmAthene's Protexia Program


    FRAMINGHAM, Mass. (AP) -- GTC Biotherapeutics Inc. said late Friday it will provide development and clinical supply manufacturing services for PharmAthene's Protexia program.
    The drug is being developed as a pre- or post-exposure therapy to treat chemical nerve agent attacks.

    GTC did not disclose financial details of the contract.

    PharmAthene, based in Annapolis, Md., is a privately-held biotechnology company.

    Shares of GTCB Biotherapeutics fell half a cent to 96.5 cents during the regular session on the Nasdaq Stock Market and added 4.5 cents to $1.01 in after-hours trading.




  16. [verwijderd] 4 maart 2007 21:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Tico () @3/3/2007 8:15:09 AM

    Als je goed leest zie je dat ik wel degelijk iets anders zeg dan jij:
    "GTCB laag omdat er veel biotech is in usa" (jij)
    vs.
    "GTCB laag omdat er USA er blijkbaar geen kwaliteit inziet." (ik)

    Toch een heel groot verschil. En daarna extrapoleer ik jouw uitspraak naar Pharming en suggereer dat Pharming dus wel eens te hoog kan staan op grond van jouw uitspraak. Gewoon om even te prikkelen.

    Ik geloof dus niet echt dat ik dingen verdraai. Jij beschuldigd Marcel hier ook constant van, maar concrete voorbeelden hiervan blijven altijd achterwege (ik heb er tenminste nooit 1 onder ogen gehad)

    Ik had overigens de 6 laatste woorden beter weg kunnen laten, want die maakten mijn reactie wellicht te aanvallend.
  17. [verwijderd] 4 maart 2007 21:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    er USA er = de USA er
    damn, dat typen op een laptop gaat nog rotter dan op een toetsenbord.
    Wanneer komt er nu 100% zuivere Voice-to-tekst software?

  21. [verwijderd] 5 maart 2007 14:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Press Release Source: GTC Biotherapeutics, Inc.


    GTC Biotherapeutics Reports Fourth Quarter and Year End 2006 Financial Results
    Monday March 5, 8:00 am ET


    FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) reported today its financial results for the fourth quarter and year ended December 31, 2006. The net loss for the fourth quarter of 2006 was $7.4 million, or $0.10 per share, compared to $8.3 million, or $0.15 per share in the fourth quarter of 2005. The net loss for the 2006 financial year was $35.3 million, or $0.53 per share, compared to $30.1 million, or $0.62 per share, for the 2005 financial year.
    ADVERTISEMENT


    "GTC went through a transformation in 2006, catalyzed by the approval of ATryn® in Europe, the first approval of a transgenically produced therapeutic product anywhere in the world," stated Geoffrey F. Cox, Ph.D., GTC's Chairman of the Board and Chief Executive Officer. "We have two important partner relationships with LEO Pharma A/S and LFB Biotechnologies which enable us to further develop ATryn® and expand our portfolio of recombinant plasma proteins. We now have a portfolio of proprietary products that are capable of driving significant future value and we have strengthened our balance sheet. As we move forward through 2007, we intend to increase our strategic focus on partnering activities to provide additional resources and momentum to our product development programs."

    ATryn®, our recombinant form of human antithrombin, was approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. Our partner LEO is planning to introduce the ATryn® product at the International Society of Thrombosis and Haemostasis conference in July 2007. In addition, LEO has obtained Scientific Advice from the European Medicines Agency on the design of a Phase II dose ranging study for the treatment of disseminated intravascular coagulation, or DIC, associated with severe sepsis. Clinical sites to initiate patient enrollment for this Phase II study are being opened. We have rights to use the Phase II data outside the LEO territories of Europe, Canada, and the Middle East, and we will receive payment from LEO for the product used in its clinical studies. In the United States, we are continuing our pivotal Phase III active and historical comparison trials of ATryn® in the hereditary deficiency indication and we expect to file for approval with the Food and Drug Administration around the end of 2007. We intend to develop ATryn® in Japan through further partnering and have begun initial discussions with potential interested partners. We believe that the worldwide market potential of ATryn® is $500 million to $700 million, primarily in acquired antithrombin deficiency indications such as DIC.

    Antithrombin is a plasma protein with anticoagulant and anti-inflammatory properties. We have developed goats that have the human antithrombin gene linked to a milk-protein promoting gene so that they express this protein in their milk. This transgenic approach provides the opportunity to produce recombinant forms of proteins, such as antithrombin, that are difficult to express in economically viable quantities in conventional production systems.

    We entered a strategic collaboration with LFB Biotechnologies, or LFB, in late 2006 that includes development of recombinant human factor VIIa, or rhFVIIa, a clotting factor in coagulation. The first indication planned for this program is in the treatment of type A and type B hemophilia where patients have developed inhibitors to clotting factors VIII or IX. An independent analyst report estimates the total worldwide market for rhFVIIa will be $2 billion by 2012, which is the year when the patents on the current marketed product, NovoSeven®, expire. The strategic collaboration with LFB includes potential development of additional recombinant human plasma proteins and monoclonal antibodies. An evaluation of these opportunities is in process. Our portfolio of recombinant plasma proteins includes recombinant human alpha-1 antitrypsin, for which we have already established a production herd and which is in preclinical development.

    Last week, we entered into an agreement with PharmAthene under which we will provide process development and clinical supply manufacturing services for Protexia®, a recombinant form of human butyrylcholinesterase produced in the milk of transgenic goats. Protexia® is being developed by PharmAthene as a pre- and post-exposure therapy for military or civilian victims of a chemical nerve agent attack. The Protexia® program, similar to the continuing supply relationship for Merrimack Pharmaceuticals' MM-093 product, will use our transgenic production technology to enable development of the partner's protein that does not express in economically viable quantities in traditional bioreactor-based methods.

    We also intend to develop through a partnering relationship our monoclonal antibody to the CD137 receptor in the human immune system. This antibody has been reported to demonstrate potential therapeutic value in preclinical models of solid tumors and autoimmune diseases. We have established production animals and are proceeding to preclinical development to support clinical studies.

    Cash Position

    We ended 2006 with approximately $43.8 million of cash and marketable securities. The third and final equity investment by LFB on January 3, 2007, as well as payments from LEO for delivery in January 2007 of Phase II clinical material that was manufactured in late 2006, provided us with additional cash and marketable securities totaling about $7 million, which on a pro forma basis would put our year-end cash and marketable securities at approximately $51 million.

    During 2006, we had
2.783 Posts
Pagina: «« 1 ... 33 34 35 36 37 ... 140 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.018
AB InBev 2 5.501
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.671
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.692
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.851
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.337
Air France - KLM 1.025 35.045
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.041
Alfen 16 24.857
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.233
AMG 971 133.359
AMS 3 73
Amsterdam Commodities 305 6.690
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.007
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.776
Arcelor Mittal 2.033 320.714
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.739
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.108
ASML 1.766 107.421
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.673
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392